High expression of P21‑activated kinase 5 protein is associated with poor survival in gastric cancer

Aburatani,Tomoki; Inokuchi,Mikito; Takagi,Yoko; Ishikawa,Toshiaki; Okuno,Keisuke; Gokita,Kentaro; Tomii,Chiharu; Tanioka,Toshiro; Murase,Hideaki; Otsuki,Sho; Uetake,Hiroyuki; Kojima,Kazuyuki; Kawano,Tatsuyuki

doi:10.3892/ol.2017.6115

High expression of P21‑activated kinase 5 protein is associated with poor survival in gastric cancer

Authors:
- Tomoki Aburatani
- Mikito Inokuchi
- Yoko Takagi
- Toshiaki Ishikawa
- Keisuke Okuno
- Kentaro Gokita
- Chiharu Tomii
- Toshiro Tanioka
- Hideaki Murase
- Sho Otsuki
- Hiroyuki Uetake
- Kazuyuki Kojima
- Tatsuyuki Kawano
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113‑8519, Japan, Department of Surgical Specialty, Tokyo Medical and Dental University, Tokyo 113‑8519, Japan
Published online on: May 3, 2017 https://doi.org/10.3892/ol.2017.6115
Pages: 404-410

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

P21-activated kinase 5 (PAK5), also termed PAK7, is one of the six members of the PAK family of serine/threonine kinases, which are downstream effectors in several cancer signaling pathways. PAK5 promotes neural outgrowth, contributes to microtubule stability and induces resistance to apoptosis. However, the clinical importance of PAK5 in gastric cancer has not been comprehensively investigated. In the present study, PAK5 expression was evaluated in gastric cancer tissue samples. Furthermore, the associations between high expression of PAK5, and clinicopathological features and prognosis were examined. PAK5 expression in primary gastric cancer specimens resected from 279 patients who underwent gastrectomy at the Tokyo Medical and Dental University Hospital was evaluated using immunohistochemistry. Of the 279 patients, 44 (15.8%) exhibited high PAK5 expression, which was significantly associated with the differentiated pathological type (differentiated vs. undifferentiated; P<0.001), depth of tumor invasion (T1 vs. T2‑T4; P<0.001), lymph node metastasis (N0 vs. N1‑N3; P<0.001), presence of distant metastasis or recurrence (present vs. absent; P=0.038), advanced tumor stage (I vs. II‑IV; P=0.001) and worse disease‑specific survival (P=0.013). In stage I‑III disease, 38/254 (15.0%) patients exhibited high PAK5 expression, and high expression of PAK5 was significantly associated with relapse‑free interval (P=0.044). PAK5 may serve an important role in tumor progression and influence the outcome of patients with gastric cancer.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et al: The global burden of cancer. JAMA Oncol. 1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lordick F, Lorenzen S, Yamada Y and Ilson D: Optimal chemotherapy for advanced gastric cancer: Is there a global consensus? Gastric Cancer. 17:213–225. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kim C, Mulder K and Spratlin J: How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 19:1046–1055. 2014. View Article : Google Scholar : PubMed/NCBI
4	Kumar R, Gururaj AE and Barnes CJ: p21-activated kinases in cancer. Nat Rev Cancer. 6:459–471. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ye DZ and Field J: PAK signaling in cancer. Cell Logist. 2:105–116. 2012. View Article : Google Scholar : PubMed/NCBI
6	Wells CM and Jones GE: The emerging importance of group II PAKs. Biochem J. 425:465–473. 2010. View Article : Google Scholar : PubMed/NCBI
7	Fang ZP, Jiang BG, Gu XF, Zhao B, Ge RL and Zhang FB: P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma. Acta Pharmacol Sin. 35:82–88. 2014. View Article : Google Scholar : PubMed/NCBI
8	Zhao ZS and Manser E: PAK and other Rho-associated kinases-effectors with surprisingly diverse mechanisms of regulation. Biochem J. 386:201–214. 2005. View Article : Google Scholar : PubMed/NCBI
9	Pandey A, Dan I, Kristiansen TZ, Watanabe NM, Voldby J, Kajikawa E, Khosravi-Far R, Blagoev B and Mann M: Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene. 21:3939–3948. 2002. View Article : Google Scholar : PubMed/NCBI
10	Kobayashi K, Inokuchi M, Takagi Y, Otsuki S, Fujimori Y, Sato Y, Yanaka Y, Higuchi K, Aburatani T, Tomii C, et al: Prognostic significance of PAK4 expression in gastric cancer. J Clin Pathol. 69:580–585. 2016. View Article : Google Scholar : PubMed/NCBI
11	Giroux V, Iovanna J and Dagorn JC: Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J. 20:1982–1991. 2006. View Article : Google Scholar : PubMed/NCBI
12	Gong W, An Z, Wang Y, Pan X, Fang W, Jiang B and Zhang H: P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. Int J Cancer. 125:548–555. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gu J, Li K, Li M, Wu X, Zhang L, Ding Q, Wu W, Yang J, Mu J, Wen H, et al: A role for p21-activated kinase 7 in the development of gastric cancer. FEBS J. 280:46–55. 2013. View Article : Google Scholar : PubMed/NCBI
14	Gu X, Wang C, Wang X, Ma G, Li Y, Cui L, Chen Y, Zhao B and Li K: Efficient inhibition of human glioma development by RNA interference-mediated silencing of PAK5. Int J Biol Sci. 11:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
15	Japanese Gastric Cancer Association, . Japanese classification of gastric carcinoma. (3rd English). Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
16	International Union Against Cancer (UICC), . TNM classification of malignant tumors. Sobin LH, Gospodarowicz MK and Wittekind C: 7th. Wiley-Blackwell; Oxford: 2009
17	Dan C, Nath N, Liberto M and Minden A: PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol. 22:567–577. 2002. View Article : Google Scholar : PubMed/NCBI
18	Timm T, Matenia D, Li XY, Griesshaber B and Mandelkow EM: Signaling from MARK to tau: Regulation, cytoskeletal crosstalk, and pathological phosphorylation. Neurodegener Dis. 3:207–217. 2006. View Article : Google Scholar : PubMed/NCBI
19	Wu X and Frost JA: Multiple Rho proteins regulate the subcellular targeting of PAK5. Biochem Biophys Res Commun. 351:328–335. 2006. View Article : Google Scholar : PubMed/NCBI
20	Cotteret S, Jaffer ZM, Beeser A and Chernoff J: p21-activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol. 23:5526–5539. 2003. View Article : Google Scholar : PubMed/NCBI
21	Cotteret S and Chernoff J: Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties. Mol Cell Biol. 26:3215–3230. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bang YJ, van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
23	Gravalos C and Jimeno A: HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
24	Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
25	Radu M, Semenova G, Kosoff R and Chernoff J: PAK signalling during the development and progression of cancer. Nat Rev Cancer. 14:13–25. 2014. View Article : Google Scholar : PubMed/NCBI